Patients with metastatic brain tumors (MBTs) require a multidisciplinary team-based approach to select the best treatment interventions. This podcast updates recommendations that address whether treatment with immune modulators benefits patients with parenchymal or leptomeningeal brain metastases in terms of local control, OS, PFS, performance status, or reduction in CNS side effects compared with standard management with chemotherapy, molecular targeted agents, SRS, WBRT, and surgical resection.

J. Bradley Elder, MD

Jeffrey J. Olson, MD

D. Ryan Ormond, MD, Phd